TCRT:NASDAQAlaunos Therapeutics, Inc. Analysis

TCRT is trading at $2.53, well below its 20‑day (2.78), 50‑day (3.01) and 200‑day (2.91) simple moving averages, signaling a clear downtrend. The 14‑day RSI sits at 33, hinting at near‑oversold conditions but not a decisive bounce. MACD is bearish, with the line under the signal and a negative histogram, reinforcing downward momentum. Volume has collapsed to 1,831 shares versus a 10‑day average of 13,570, underscoring thin liquidity. A 30‑day volatility of roughly 36% and a beta near 1.1 indicate the stock swings more than the broader market, amplifying risk.
Fundamentally, the company posted $5 M in revenue with a 25% YoY decline, zero gross margin and an operating loss exceeding 300%. Cash burn is severe at about $2.9 M annually, leaving only $1.4 M in cash – barely six months of runway. The forward P/E is negative and the price‑to‑sales ratio tops 1,200, suggesting the market is pricing speculative future upside. Compounding these issues, TCRT received a Nasdaq notice for non‑compliance with equity rules, a material red flag for short‑term investors. Overall, the blend of technical weakness, financial distress, and compliance concerns makes the stock highly risky at current levels.